The drug candidate tipifarnib (Zarnestra) is being clinically studied for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma after progression on platinum therapy.
Head and Neck Cancer Year in Review
Researchers found that there is an increasing incidence of late stage head and neck cancer in the U.S., highlighting the need for continuous public health efforts toward early detection.
A new possible surveillance model suggests scanning patients with head and neck cancer treated with radiotherapy less frequently could be more cost-effective and time-effective.
A new inhibitor may help patients with a certain subset of head and neck squamous cell carcinoma.
The phase III KEYNOTE-048 study compared pembrolizumab plus chemotherapy vs the EXTREME regimen in patients with recurrent/metastatic head and neck cancer.
For patients undergoing primary treatment for head and neck cancer, sexuality was significantly impacted in many patients both prior to and during cancer treatment.